Inicio › Dermatitis atópica (eccema) › Alabama
Ensayos clínicos de Dermatitis atópica (eccema) en Alabama
9 estudios sobre Dermatitis atópica (eccema) buscan participantes en Alabama.
Ciudades en Alabama
Texto oficial del estudio (inglés)
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- Cahaba Dermatology & Skin Health Center- Site Number : 8400006, Birmingham
- River Region Dermatology and Laser- Site Number : 8400041, Montgomery
ReclutandoEstudio observacional
Edades de 12 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT07290803Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Birmingham
- Novartis Investigative Site, Birmingham
ReclutandoFase 2
Edades de 18 a 100 · Todos los sexos · Actualizado el 28 sept 2026 · NCT06947993Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Birmingham
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 25 sept 2026 · NCT07298395First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
- Cahaba Dermatology & Skin Health Center, LLC, Birmingham
ReclutandoFase 1Se aceptan voluntarios sanos
Edades de 18 a 65 · Todos los sexos · Actualizado el 25 sept 2026 · NCT07527923A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Cahaba Dermatology & Skin Health Center, Birmingham
ReclutandoFase 3
Edades de 2 a 11 · Todos los sexos · Actualizado el 25 sept 2026 · NCT06807281A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- AllerVie Clinical Research, Birmingham
- Cahaba Dermatology and Skin Health Center, Birmingham
ReclutandoFase 2
Edades de 18 a 65 · Todos los sexos · Actualizado el 28 ago 2026 · NCT07599813A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Leo Pharma Investigational site, Birmingham
ReclutandoFase 3
6 Months – 11 Years · Todos los sexos · Actualizado el 7 jul 2026 · NCT06311682A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Cahaba Dermatology & Skin Health Center /ID# 263855, Birmingham
ReclutandoFase 3
Edades de 18 a 63 · Todos los sexos · Actualizado el 6 jul 2026 · NCT06389136A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Allervie Clinical Research, Birmingham
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 may 2026 · NCT05995964De ClinicalTrials.gov, datos obtenidos el 5 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.